Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNASTY-Breast02: DB-1303 versus investigator's choice chemotherapy in HER2-low HR-positive metastatic breast cancer
2023-507333-17-00Phase 3Authorised
- Sponsor
- Duality Biotherapeutics
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of trastuzumab pamirtecan in breast cancer (2 arms), sponsored by Duality Biotherapeutics. Primary endpoint: Progression-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
trastuzumab pamirtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-507333-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507333-17-00.